OptimizeRx Corporation (OPRX)
NASDAQ: OPRX · Real-Time Price · USD
6.54
-0.16 (-2.32%)
Jul 20, 2026, 1:45 PM EDT - Market open
OptimizeRx Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, OptimizeRx stock has a consensus rating of "Strong Buy" and an average price target of $12.4. The average 1-year stock price forecast is 89.75% higher than the current stock price, while the lowest is $9.00 (+37.72%) and the highest is $18 (+175.44%).
Price Target: $12.4 (+89.75%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on May 13, 2026.
Analyst Ratings
The average analyst rating for OptimizeRx stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +53.02% | May 13, 2026 |
| Stephens | Stephens | Hold Reiterates $7 | Hold | Reiterates | $7 | +7.12% | May 13, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $17 → $14 | Buy | Reiterates | $17 → $14 | +114.23% | May 13, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | May 13, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $18 | Buy | Reiterates | $18 | +175.44% | May 13, 2026 |
Financial Forecast
Revenue This Year
97.41M
from 109.43M
Decreased by -10.98%
Revenue Next Year
108.89M
from 97.41M
Increased by 11.79%
EPS This Year
0.94
from 1.05
Decreased by -10.67%
EPS Next Year
1.09
from 0.94
Increased by 16.42%
EPS and Forward PE are based on non-GAAP adjusted numbers.